Key Points
- CFO Kevin Tan sold 26,837 shares on Feb. 2 at an average price of $6.44 for about $172,830, leaving him with 108,984 shares (a ~19.8% drop in his holding).
- Large, concurrent insider selling occurred the same day — multiple senior executives sold a combined ~226,000 shares for roughly $1.45M, with individual position reductions in the ~20–25% range, a move that could weigh on investor sentiment.
- Shares trade near $6.43 with a market cap of about $501M and negative earnings (expected EPS ~-2.84 this year), yet analysts show an average rating of "Moderate Buy" and a consensus price target of about $14.70.
Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CFO Kevin Tan sold 26,837 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $172,830.28. Following the completion of the transaction, the chief financial officer directly owned 108,984 shares of the company's stock, valued at approximately $701,856.96. The trade was a 19.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.
Kevin Tan also recently made the following trade(s):
- On Tuesday, January 13th, Kevin Tan sold 5,704 shares of Solid Biosciences stock. The shares were sold at an average price of $5.27, for a total value of $30,060.08.
Solid Biosciences Trading Down 0.5%
Shares of NASDAQ SLDB opened at $6.43 on Tuesday. The firm's 50-day moving average is $5.75 and its 200-day moving average is $5.71. The firm has a market capitalization of $500.96 million, a PE ratio of -2.58 and a beta of 2.67. Solid Biosciences Inc. has a 1 year low of $2.41 and a 1 year high of $7.37.
Solid Biosciences (NASDAQ:SLDB - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.06). As a group, equities research analysts anticipate that Solid Biosciences Inc. will post -2.84 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of SLDB. Legal & General Group Plc increased its stake in Solid Biosciences by 208.6% in the second quarter. Legal & General Group Plc now owns 6,011 shares of the company's stock valued at $29,000 after acquiring an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company's stock worth $33,000 after purchasing an additional 4,534 shares in the last quarter. Creative Planning purchased a new stake in Solid Biosciences during the 2nd quarter valued at $57,000. Russell Investments Group Ltd. lifted its holdings in Solid Biosciences by 142.0% in the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company's stock valued at $63,000 after acquiring an additional 5,991 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey grew its holdings in shares of Solid Biosciences by 233.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company's stock valued at $74,000 after purchasing an additional 10,585 shares in the last quarter. 81.46% of the stock is currently owned by institutional investors.
Key Solid Biosciences News
Here are the key news stories impacting Solid Biosciences this week:
- Positive Sentiment: Analysts maintain a constructive view — SLDB has an average analyst rating of "Moderate Buy," which may support demand despite near-term weakness. Analyst Rating Article
- Neutral Sentiment: Technical/market context is mixed — trading volume is slightly above average and the share price is within its 52-week range ($2.41–$7.37), suggesting limited directional conviction from broader market participants. (Market data referenced.)
- Negative Sentiment: Large, concurrent insider selling — multiple senior executives (CEO Alexander Cumbo, COO David Howton, CTO Paul Herzich, CFO Kevin Tan and other insiders) sold sizable positions on Feb 2 at an average price of $6.44. Combined disclosed sales total roughly 226k shares for about $1.45M, with individual position reductions in the ~20–25% range — a signal that could weigh on investor sentiment and share demand. Representative SEC filings: CEO Filing CTO Filing
Analyst Upgrades and Downgrades
Several equities analysts have commented on the stock. Chardan Capital reiterated a "buy" rating and issued a $15.00 price objective on shares of Solid Biosciences in a report on Tuesday, November 4th. Wall Street Zen downgraded Solid Biosciences from a "hold" rating to a "sell" rating in a research report on Sunday, October 19th. Barclays set a $9.00 price objective on shares of Solid Biosciences and gave the company an "overweight" rating in a research note on Tuesday, November 4th. Weiss Ratings restated a "sell (d-)" rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. Finally, JPMorgan Chase & Co. decreased their price target on shares of Solid Biosciences from $13.00 to $11.00 and set an "overweight" rating for the company in a research report on Wednesday, November 5th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $14.70.
Get Our Latest Stock Analysis on SLDB
About Solid Biosciences
(
Get Free Report)
Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company's primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.
Solid's lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
